TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA issued Import Alert 89-04 covering specified Olympus medical devices manufactured in Japan, citing outstanding quality-system regulation violations. The alert blocks future shipments of listed devices from entering the United States; it does not automatically require providers to stop using devices already in service.
The U.S. Food and Drug Administration says it has issued Import Alert 89-04 for specified medical devices made in Japan by Olympus Medical Systems Corporation and its subsidiaries, meaning future shipments of listed models will be refused entry to the United States. The agency cites outstanding quality-system regulation violations and advises providers to check device model numbers and identifiers before making decisions about equipment already in use.
The alert covers selected models in several product categories: bronchoscopes, ureterorenoscopes, laparoscopes, automated endoscope reprocessors, ingestible gastrointestinal capsule imaging systems and enteroscopes. These devices are used for procedures and visualization in the respiratory and urinary tracts, abdomen and pelvis, and small intestine, as well as for reprocessing endoscopes. The alert applies to the models listed by the FDA, not automatically to every Olympus product.
The FDA’s accompanying table identifies devices by name, version or model, and device identifier. The supplied list includes, among others, bronchoscopes and bronchovideoscopes, Endoeye videoscopes, and OER-series endoscope reprocessors. Providers are directed to consult the agency’s table and use the model and Unique Device Identifier (UDI) information to determine whether a particular device is covered.
The agency says the import alert does not apply to related products such as replacement parts, connectors or single-use consumables used with the listed devices. For covered devices already in use, the FDA says providers may continue using them if they are not experiencing problems. It advises against using damaged devices or devices that fail a leak test, and calls for adherence to labeling, cleaning and reprocessing instructions, plus routine inspection and maintenance.
How the Alert Affects Hospitals
The action primarily affects future U.S. supply of the specified models: shipments covered by Import Alert 89-04 can be refused entry. That could matter to hospitals and other providers planning equipment purchases, replacements or service needs, although the FDA material does not quantify the number of devices or facilities affected, or describe the availability of alternatives.
For clinicians, the agency’s guidance distinguishes the import restriction from a blanket instruction to remove devices already in service. The FDA says continued use can be considered when a device is not causing problems, while also directing providers to follow safety and maintenance instructions and to check whether a particular product has been recalled. The agency does not recommend canceling or delaying procedures without a discussion between the provider and patient about the benefits and risks.
The alert also has implications for purchasing and inventory teams. Checking exact model and UDI details can help distinguish covered equipment from related products that are outside the alert. Providers are also asked to report adverse events promptly so the FDA can identify and better understand potential risks.
Olympus bronchoscopes model replacement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Olympus Compliance History
The FDA’s letter places the import alert within a series of agency actions concerning Olympus. It says the agency has previously issued warning letters and import alerts related to current good manufacturing practice requirements and reporting obligations, including recall reporting. The FDA describes its current concerns as outstanding quality-system violations despite what it calls extensive and ongoing efforts to address compliance issues.
The agency says it monitors corrective actions related to the ongoing device quality concerns. The October 20, 2026, provider letter presents the import alert as a measure to prevent future shipments of specified devices from entering the country, while noting that the FDA will continue to inform health care providers and the public if additional information becomes available.
The FDA’s UDI system is intended to identify medical devices sold in the United States from manufacturing through distribution and patient use. The agency points providers to the AccessGUDID database as a way to identify devices. The source material lists the alert’s effective date as June 24, 2025, while the provider letter is dated October 20, 2026; it does not explain that timing difference.
“Despite extensive and ongoing efforts to address compliance issues, the FDA continues to have concerns related to outstanding Quality System regulation violations by Olympus.”
— U.S. Food and Drug Administration
endoscope reprocessors compatible with Olympus devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Coverage and Safety Questions
The supplied FDA material does not state how many devices or health care facilities are affected, whether shipments have already been refused under the alert, or how long the import restriction is expected to remain in place. It also does not provide a complete explanation of the specific quality-system violations in this provider letter or detail what corrective actions Olympus has taken in response.
The listed models and identifiers should be checked against the FDA’s full table; the source material provided here contains only part of the table. The letter also says some devices covered by the alert may have been recalled, but it does not identify every affected recall in the text provided. Providers are directed to follow the relevant company recall notification if their device was recalled. The relationship between the table’s stated June 24, 2025 effective date and the letter’s October 20, 2026 date is not explained.
gastrointestinal capsule imaging systems
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
FDA Monitoring and Provider Checks
The FDA says it will continue monitoring corrective actions related to Olympus’s device-quality violations and will share further information if it becomes available. The agency does not give a deadline for resolving the compliance concerns or indicate when it might revise or withdraw the import alert.
In the meantime, providers can check equipment against the FDA’s model and UDI list and use AccessGUDID to help identify devices. The agency advises facilities to follow manufacturer labeling and reprocessing instructions, maintain inspection and maintenance schedules, avoid using damaged devices or those that fail leak tests, and check recall notices for product-specific directions. It also asks health care professionals to report adverse events promptly.
medical device cleaning and maintenance kits
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which Olympus devices are covered by the import alert?
The FDA alert applies to specified models made in Japan, across categories including bronchoscopes, ureterorenoscopes, laparoscopes, endoscope reprocessors, gastrointestinal capsule imaging systems and enteroscopes. Providers should compare the exact model and UDI with the FDA’s full list; the alert does not cover every Olympus device.
Should providers stop using devices already in service?
Not automatically, according to the FDA. The agency says devices subject to the alert that are already in use may continue to be used if they are not experiencing problems. It advises against using damaged devices or those that fail a leak test, and says providers should follow any applicable recall instructions.
Are replacement parts and single-use supplies included?
The FDA says the import alert does not apply to related products such as replacement parts, connectors or single-use consumables used with devices covered by the alert.
Does the FDA advise canceling procedures?
No blanket cancellation instruction is given. The FDA says procedures should not be canceled or delayed without a discussion between the health care provider and patient about the benefits and risks of proceeding.
Why did the FDA issue the alert?
The agency says it continues to have concerns about outstanding quality-system regulation violations at Olympus despite ongoing efforts to address compliance issues. The alert is intended to prevent future shipments of the specified devices from entering the United States.
Source: primary
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
